Pharnext Logo

Pharnext

ALPHA | Euronext Growth

Overview

Corporate Details

ISIN(s):
FR0011191287 (+4 more)
LEI:
969500KJGF9ZUYXSMJ27
Country:
France
Address:
9 RUE DES FILLES SAINT-THOMAS, 75002 PARIS
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Our company Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical needs. Our drug Candidates Two drug candidates are currently in clinical development: PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 for Alzheimer’s disease. Both of our lead assets originated from the Pleotherapy R&D approach.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-08-27 13:00
Legal Proceedings Report
Ouverture d'une procédure de liquidation judiciaire
French 194.1 KB
2024-08-01 18:00
Share Issue/Capital Change
Ajustement de la valeur nominale
French 189.9 KB
2024-07-18 18:00
Capital/Financing Update
Point concernant l'accord de financement en obligations convertibles accordé pa…
French 194.2 KB
2024-07-15 18:00
Legal Proceedings Report
Demande d'ouverture d'une procédure de liquidation judiciaire
French 193.2 KB
2024-07-10 08:00
Capital/Financing Update
Pharnext fait un point sur sa situation financière
French 191.6 KB
2024-07-04 20:00
Legal Proceedings Report
Pharnext annonce la résiliation du contrat de financement accordé par Néovacs
French 232.3 KB
2024-07-03 08:00
Capital/Financing Update
Pharnext fait un point sur les conséquences de sa situation stratégique et fina…
French 208.2 KB
2024-07-01 18:30
Share Issue/Capital Change
Information relative au nombre total de droits de vote et d'actions composant l…
French 185.7 KB
2024-06-28 08:00
Legal Proceedings Report
Pharnext fait un point d'étape sur les dernières avancées majeures d'un point d…
French 209.3 KB
2024-06-18 18:30
Post-Annual General Meeting Information
Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 jui…
French 194.9 KB
2024-06-05 18:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total de droits de vote et d'actions composant l…
French 181.3 KB
2024-05-29 18:00
Share Issue/Capital Change
Ajustement de la valeur nominale
French 190.9 KB
2024-05-07 19:10
Share Issue/Capital Change
Ajustement de la valeur nominale
French 190.6 KB
2024-05-06 18:00
Pre-Annual General Meeting Information
Pharnext convoque ses actionnaires en assemblée générale le 10 juin 2024
French 194.7 KB
2024-05-02 18:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total de droits de vote et d'actions composant l…
French 195.4 KB

Automate Your Workflow. Get a real-time feed of all Pharnext filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pharnext via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany MOR
Mycodern Spolka Akcyjna Logo Poland MCD
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom ONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.